MedTrace Logo

Virtual Reality Exposure Therapy for Speech Anxiety Using Commercial Hardware and Software

NCT03001154 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-03-07

No results posted yet for this study

Summary

Virtual Reality Exposure Therapy (VRET) is an efficacious treatment of fear and anxiety, but because of the high financial costs and technical complexity of the past generation of VR hardware, there has been no large-scale implementation of this promising treatment. The present study will investigate whether off-the-shelf, commercial VR hardware and software can be used as stimuli material to conduct in-session exposure therapy for speech anxiety. The study will recruit n=25+25 participants from the general public suffering from substantial speech anxiety, who will be randomized to either a waiting-list, or one-session VRET with a therapist, followed by four weeks of a progressive maintenance program encouraging in-vivo exposure. The waiting-list group will then receive an Internet-delivered VRET treatment program.

Conditions

  • Social Phobia
  • Anxiety
  • Behavior Therapy

Interventions

BEHAVIORAL

Face-to-face Virtual Reality Exposure Therapy

In session, systematic, hierarchical exposure to feared stimuli with therapist.

BEHAVIORAL

Internet-administered Virtual Reality Exposure Therapy

Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program

OTHER

Waiting-list

Weekly assessments of public speaking

Sponsors & Collaborators

  • Stockholm University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-05-31
Completion
2018-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001154 on ClinicalTrials.gov